Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Nuvation Bio
company
About
Nuvation Bio is a biopharmaceutical company.
- 101 - 250
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $275M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2018
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Nuvation Bio, is a privately-held biopharmaceutical company currently operating in stealth mode that is focused on the development of next generation therapies that will target the foremost unmet needs in oncology. Nuvation Bio's proprietary portfolio includes seven novel and mechanistically distinct oncology programs, each with multiple drug development candidates. Nuvation Bio was founded in 2018 by industry veteran David Hung, M.D., who previously founded and served as President and Chief Executive Officer of Medivation. Nuvation Bio has offices in New York and San Francisco.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$275M
Nuvation Bio has raised a total of
$275M
in funding over 2 rounds. Their latest funding was raised on
Oct 28, 2019 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 28, 2019 | Series A | $275M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Nuvation Bio is funded by 1 investors.
Pavilion Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Pavilion Capital
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
